VBCC Oct 2014 | Vol 5 | No 8

Page 1

OCTOBER 2014 VOL 5 NO 8

INTEGRATING COST, QUALITY, ACCESS INTO CLINICAL DECISION-MAKING IN ONCOLOGY www.ValueBasedCancerCare.com

Reimbursement Reform in Oncology Must Reward for Quality of Care

Cancer Center profile

New Mexico Oncology Medical Home Interview with Barbara L. McAneny, MD

ASCO proposes a new payment model By Dana Butler

Jeffery Ward, MD

T

he current fee-for-service reimbursement model used in oncology has jeopardized value-based cancer care, according to Jeffery Ward, MD, a member of the American Society of Clinical Oncology (ASCO) Workgroup on Payment Reform. He dis-

C

ancer care has been undergoing transformation in recent years. The oncology medical home is one model that has shown improved outcomes and patient satisfaction. What are the characteristics of the oncology medical home and how is it different from other cancer centers in the United States? Value-Based Cancer Care (VBCC) discussed these questions with Barbara L. McAneny, MD, CEO, New Mexico Oncology Hematology Consultants, who established the New Mexico Cancer Center’s Oncology Medical Home as part of the COME HOME award from the Center for Medicare and Medicaid Innovation. VBCC: What are the characteristics of an oncology medical home? Barbara L. McAneny, MD: The oncology medical home concept is centered around the idea of “home.” Home is where you go when you need help. The goal of the oncology medical home is to provide all the services that patients Continued on page 25

Fourth Conference

Patient-Centered Oncology Medical Home Improves Health Outcomes at Lower Costs to Patients and Payers By Wayne Kuznar Los Angeles, CA—Oncology practices are evolving in an era of cost containment and a renewed focus on quality. At the Fourth Annual Conference of the Association for Value-Based Cancer Care, John D. Sprandio, MD, Chief of Medical Oncology and Hematology at Oncology Management Services, Ltd, a single-specialty practice trans-

© 2014 Engage Healthcare Communications, LLC

formation company, discussed how his Pennsylvania-based integrated care delivery model has evolved to meet the parallel needs of oncology payers and patients with cancer. Cancer care is undergoing transition. Community-based oncologists have gone from providing approximately 85% of the cancer care in the United

Continued on page 42

cussed the group’s novel proposal for consolidated cancer care at the Community Oncology Town Hall during the 2014 annual meeting of ASCO. “Working toward a better payment system for oncology care, instead of just complaining about the one that we have, Continued on page 8

ESMO 2014 Highlights

CLEOPATRA: Record-Breaking Survival in HER2 Metastatic Breast Cancer by Adding Pertuzumab Dual HER2 blockade a new standard of care By Phoebe Starr Madrid, Spain—Final results from the CLEOPATRA (Clinical Evaluation of Pertuzumab and Trastuzumab) trial show that dual HER2 blockade with the combination of pertuzumab and trastuzumab plus chemotherapy ex-

tended overall survival (OS) by almost 16 months compared with trastuzumab plus chemotherapy alone in patients with HER2-positive metastatic breast cancer. This should become the new standard of care for Continued on page 12

inside VALUE PROPOSITIONS . . . . . . . . . . . . . . . . 7 Medicare covers noninvasive CRC test NCI launches new study of exceptional responders to cancer therapy ECONOMICS OF CANCER CARE . . . . Cost-benefit of robotics in head and neck cancers Medicaid reimbursement impacts cancer screening rates

8

ESMO 2014 Highlights . . . . . . . . . . . . 12 PD-1 blocker nivolumab impressive in melanoma BRAF-MEK combo inhibitor improves survival VBCC PERSPECTIVE . . . . . . . . . . . . . . . . . . 28 Logistic toxicity: Obstacles to efficient cancer care delivery

PROSTATE CANCER . . . . . . . . . . . . . . . . . . 30 New guideline for systemic therapy IN THE LITERATURE . . . . . . . . . . . . . . . . . . 31 Novel mutations help in overcoming lung cancer treatment resistance END-OF-LIFE CARE . . . . . . . . . . . . . . . . . . . 36 IOM on US end-of-life care FDA UPDATE . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41 New combination agent for CINV prevention 4TH CONFERENCE . . . . . 42 Oncology medical home improves outcomes Does CER have value in oncology? DRUG UPDATE . . . . . . . . . . . . . . . . . . . . . . . . . 48 Beleodaq for relapsed/refractory peripheral T-cell lymphoma


Turn static files into dynamic content formats.

Create a flipbook
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.
VBCC Oct 2014 | Vol 5 | No 8 by Value-Based Cancer Care - Issuu